PubRank

M D Kazatchkine

Author PubWeight™ 242.47‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000 3.95
2 Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol 1979 3.50
3 Natural autoantibodies. Curr Opin Immunol 1995 3.00
4 Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998 2.90
5 Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984 2.47
6 Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000 1.97
7 Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol 1985 1.91
8 Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in seventy-five cases of renal diseases: loss of C3b receptor antigen in focal hyalinosis and in proliferative nephritis of systemic lupus erythematosus. J Clin Invest 1982 1.86
9 Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis 2000 1.86
10 Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. Nephrol Dial Transplant 1994 1.80
11 Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001 1.76
12 Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998 1.62
13 Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med 1979 1.53
14 Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol 2000 1.53
15 Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci U S A 1987 1.49
16 Mapping of the region of complement receptor (CR) 1 required for Plasmodium falciparum rosetting and demonstration of the importance of CR1 in rosetting in field isolates. J Immunol 2000 1.48
17 Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989 1.46
18 Comparative assessment of five alternative methods for CD4+ T-lymphocyte enumeration for implementation in developing countries. J Acquir Immune Defic Syndr 2001 1.44
19 Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med 1991 1.44
20 Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 1998 1.43
21 A new type of acquired C1 inhibitor deficiency associated with systemic lupus erythematosus. Arthritis Rheum 2001 1.43
22 Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 1998 1.41
23 Binding sites for endotoxins (lipopolysaccharides) on human monocytes. J Immunol 1991 1.39
24 Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 1991 1.37
25 Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989 1.35
26 Immunohistochemical study of the C5b-9 complex of complement in human kidneys. Kidney Int 1986 1.33
27 Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers. Clin Diagn Lab Immunol 2000 1.26
28 Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. Proc Natl Acad Sci U S A 1987 1.23
29 Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 1981 1.23
30 Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999 1.20
31 Persistent expansion, in a human immunodeficiency virus-infected person, of V beta-restricted CD4+CD8+ T lymphocytes that express cytotoxicity-associated molecules and are committed to produce interferon-gamma and tumor necrosis factor-alpha. J Infect Dis 1998 1.20
32 Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990 1.20
33 Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991 1.20
34 Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis 2001 1.20
35 Invariance and restriction toward a limited set of self-antigens characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of healthy adults. Proc Natl Acad Sci U S A 1995 1.18
36 Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol 1991 1.12
37 Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur J Immunol 1993 1.11
38 Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1alpha and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis 1997 1.11
39 Induction of cell-associated interleukin 1 through stimulation of the adhesion-promoting proteins LFA-1 (CD11a/CD18) and CR3 (CD11b/CD18) of human monocytes. Eur J Immunol 1990 1.11
40 C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J Immunol 1987 1.10
41 Suboptimal C3b/C3bi deposition and defective yeast opsonization. I. Evidence for the absence of essential co-factor activity. Clin Exp Immunol 1985 1.10
42 Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998 1.09
43 Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. J Infect Dis 2000 1.08
44 Active and selective transcytosis of cell-free human immunodeficiency virus through a tight polarized monolayer of human endometrial cells. J Virol 2001 1.08
45 The self-reactive antibody repertoire of normal human serum IgM is acquired in early childhood and remains conserved throughout life. Scand J Immunol 1996 1.08
46 Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis. Clin Microbiol Infect 2000 1.08
47 Induction of IL-1 release through stimulation of the C3b/C4b complement receptor type one (CR1, CD35) on human monocytes. J Immunol 1990 1.06
48 Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab 2000 1.04
49 Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol 1999 1.03
50 Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996 1.03
51 Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 1988 1.03
52 Catalytic activity of anti-thyroglobulin antibodies. J Immunol 1995 1.02
53 Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy. Lancet 1998 1.02
54 Relative inefficiency of terminal complement activation. J Immunol 1988 1.02
55 Idiotypic interactions between normal human polyspecific IgG and natural IgM antibodies. Eur J Immunol 1990 1.02
56 Natural autoantibodies and complement promote the uptake of a self antigen, human thyroglobulin, by B cells and the proliferation of thyroglobulin-reactive CD4(+) T cells in healthy individuals. Eur J Immunol 2001 1.01
57 Analysis of the natural human IgG antibody repertoire: life-long stability of reactivities towards self antigens contrasts with age-dependent diversification of reactivities against bacterial antigens. Eur J Immunol 1995 1.01
58 Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci U S A 1992 1.01
59 Distribution in clusters of complement receptor type one (CR1) on human erythrocytes. J Immunol 1989 1.01
60 Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993 1.01
61 gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway. Immunology 1988 1.00
62 Membrane molecules which trigger the production of interleukin-1 and tumor necrosis factor-alpha by lipopolysaccharide-stimulated human monocytes. Eur J Immunol 1992 1.00
63 Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol 1994 0.99
64 Human T cells and interleukin 4 inhibit the release of interleukin 1 induced by lipopolysaccharide in serum-free cultures of autologous monocytes. Eur J Immunol 1989 0.99
65 Functional role of the alpha-chain of complement receptor type 3 in human eosinophil-dependent antibody-mediated cytotoxicity against schistosomes. J Immunol 1987 0.98
66 Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor. J Immunol 1986 0.97
67 CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin Exp Immunol 1993 0.97
68 Analysis of natural and disease-associated autoantibody repertoires: anti-endothelial cell IgG autoantibody activity in the serum of healthy individuals and patients with systemic lupus erythematosus. Int Immunol 1994 0.97
69 Analysis of the normal human IgG antibody repertoire. Evidence that IgG autoantibodies of healthy adults recognize a limited and conserved set of protein antigens in homologous tissues. J Immunol 1995 0.97
70 Detection of Y chromosome DNA as evidence of semen in cervicovaginal secretions of sexually active women. Clin Diagn Lab Immunol 2001 0.97
71 Inhibition of complement activation by natural sulfated polysaccharides (fucans) from brown seaweed. Mol Immunol 1994 0.97
72 Triggering of complement receptors CR1 (CD35) and CR3 (CD11b/CD18) induces nuclear translocation of NF-kappa B (p50/p65) in human monocytes and enhances viral replication in HIV-infected monocytic cells. J Immunol 1995 0.97
73 Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 1999 0.96
74 Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang 1993 0.96
75 The complement system in atherosclerosis. Atherosclerosis 1988 0.96
76 Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996 0.96
77 Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells. J Immunol 1991 0.96
78 Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV. Scand J Immunol 1993 0.96
79 Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 1999 0.95
80 Immunohistochemical study of complement S protein (Vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b-9 terminal complex. Clin Exp Immunol 1989 0.95
81 Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clin Exp Med 2005 0.95
82 Stability of natural self-reactive antibody repertoires during aging. J Clin Immunol 1999 0.95
83 Suboptimal C3b/C3bi deposition and defective yeast opsonization. II. Partial purification and preliminary characterization of an opsonic co-factor able to correct sera with the defect. Clin Exp Immunol 1985 0.95
84 Autoantibodies to the collagen-like region of C1q are strongly associated with classical pathway-mediated hypocomplementemia in systemic lupus erythematosus. Lupus 1996 0.95
85 The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients. Antiviral Res 2000 0.94
86 Lysine residues, but not carbohydrates, are required for the regulatory function of H on the amplification C3 convertase of complement. J Immunol 1984 0.94
87 Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. J Autoimmun 2001 0.94
88 Mouse monoclonal antibodies to the human C3b receptor. Mol Immunol 1985 0.94
89 Guinea pig erythrocytes, after their contact with influenza virus, acquire the ability to activate the human alternative complement pathway through virus-induced desialation of the cells. J Immunol 1982 0.94
90 Human eosinophils express CR1 and CR3 complement receptors for cleavage fragments of C3. Cell Immunol 1986 0.94
91 On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1990 0.94
92 Regulation of the human alternative complement pathway: formation of a ternary complex between factor H, surface-bound C3b and chemical groups on nonactivating surfaces. Eur J Immunol 1989 0.94
93 Monoclonal antibodies to the human C3b/C4b receptor (CR1) enhance specific B cell differentiation. J Immunol 1987 0.93
94 Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule. Mol Immunol 1988 0.93
95 Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 1997 0.93
96 Compartmentalization of the IgG immune response to HIV-1 in breast milk. AIDS 1999 0.92
97 Genetically related human immunodeficiency virus type 1 in three adults of a family with no identified risk factor for intrafamilial transmission. J Virol 1998 0.92
98 Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 1995 0.92
99 Secretory leukocyte protease inhibitor in colostrum and breast milk is not a major determinant of the protection of early postnatal transmission of HIV. AIDS 1999 0.92
100 Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci 2003 0.92
101 Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin Immunol Immunopathol 1992 0.92
102 Altered control of self-reactive IgG by autologous IgM in patients with warm autoimmune hemolytic anemia. Blood 2000 0.91
103 Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates. Blood 1993 0.91
104 Genomic determination of the CR1 (CD35) density polymorphism on erythrocytes using polymerase chain reaction amplification and HindIII restriction enzyme digestion. J Immunol Methods 1991 0.91
105 Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol 2001 0.91
106 Genetic analysis of CR1 expression on erythrocytes of patients with systemic lupus erythematosus. Arthritis Rheum 1989 0.91
107 Polyreactivity is a property of natural and disease-associated human autoantibodies. Scand J Immunol 1993 0.91
108 Isolation and characterization of the C3b-binding entity of C3b-receptor from human erythrocytes. Immunol Lett 1982 0.90
109 Complement activation by gp160 glycoprotein of HIV-1. AIDS Res Hum Retroviruses 1993 0.90
110 In vivo induction of interleukin-1 during hemodialysis. Kidney Int 1989 0.89
111 CR1(CD35) and CR2(CD21) complement C3 receptors are expressed on normal human thymocytes and mediate infection of thymocytes with opsonized human immunodeficiency virus. Eur J Immunol 1994 0.89
112 The human alternative complement pathway: biology and immunopathology of activation and regulation. Prog Allergy 1982 0.89
113 Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun 1995 0.89
114 High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis 2000 0.88
115 Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 1993 0.88
116 Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation. Nephrol Dial Transplant 1994 0.88
117 Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement. J Immunol 1983 0.88
118 Normal human serum contains natural antibodies reactive with autologous ABO blood group antigens. Blood 1999 0.88
119 Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position. Mol Immunol 1987 0.88
120 HIV infection is associated with the spontaneous production of interleukin-1 (IL-1) in vivo and with an abnormal release of IL-1 alpha in vitro. AIDS 1989 0.88
121 Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line. J Immunol 1988 0.88
122 Acute cytomegalovirus infection in AIDS patients with CD4 counts above 100 x 10(6) cells/l following combination antiretroviral therapy including protease inhibitors. AIDS 1997 0.87
123 Characterization of monoclonal antihuman-B-cell antibody BL13 as an anti-C3d-receptor (CR2) antibody. Scand J Immunol 1986 0.87
124 A V region-connected autoreactive subfraction of normal human serum immunoglobulin G. Eur J Immunol 1992 0.87
125 Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989 0.87
126 Induction in mucosa of IgG and IgA antibodies against parenterally administered soluble immunogens. Scand J Immunol 2001 0.87
127 Soluble CD21 (sCD21) forms biologically active complexes with CD23: sCD21 is present in normal plasma as a complex with trimeric CD23 and inhibits soluble CD23-induced IgE synthesis by B cells. Int Immunol 1998 0.87
128 A shift in encephalitogenic T cell cytokine pattern is associated with suppression of EAE by intravenous immunoglobulins (IVIg). Mult Scler 1997 0.86
129 Soluble CD16 inhibits CR3 (CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1. J Immunol 2001 0.86
130 Human liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. An immunohistochemical study. Lab Invest 1989 0.86
131 Analysis of human self-reactive antibody repertoires by quantitative immunoblotting. J Immunol Methods 2000 0.85
132 Anti-cardiolipin antibodies are associated with anti-endothelial cell antibodies but not with anti-beta 2 glycoprotein I antibodies in HIV infection. Clin Immunol Immunopathol 1995 0.85
133 Intramedullary abscess resulting from disseminated cryptococcosis despite immune restoration in a patient with AIDS. J Infect 2002 0.85
134 Immunohistochemical analysis of C3 cleavage fragments, factor H, and the C5b-9 terminal complex of complement in de novo membranous glomerulonephritis occurring in patients with renal transplant. Clin Nephrol 1986 0.85
135 Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV. Scand J Immunol 1992 0.85
136 Quantitation of human immunodeficiency virus type 1 (HIV-1) RNA in cell-free cervicovaginal secretions: comparison of reverse transcription-PCR amplification (AMPLICOR HIV-A MONITOR 1.5) with enhanced-sensitivity branched-DNA assay (Quantiplex 3.0). J Clin Microbiol 2001 0.85
137 Immunohistochemical study of Ia antigen in the normal and diseased human kidney. Kidney Int 1984 0.85
138 Antiretroviral therapy suppresses the constitutive production of interleukin-1 associated with human immunodeficiency virus infection. J Infect Dis 1995 0.85
139 Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur J Immunol 1999 0.85
140 Immunoglobulins and the regulation of autoimmunity through the immune network. Clin Exp Rheumatol 1996 0.84
141 Dissociation between the interleukin 1-inducing capacity and Limulus reactivity of lipopolysaccharides from gram-negative bacteria. Cytokine 1990 0.84
142 Immunopathologic and clinical features of hemolytic anemia due to cold agglutinins. Semin Hematol 1991 0.84
143 Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype. Clin Exp Rheumatol 1997 0.84
144 Renal aspergilloma in AIDS. Am J Med 1993 0.84
145 Anti-C3b-receptor (CR1) antibodies in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1986 0.84
146 Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood 1992 0.84
147 Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz. AIDS 2000 0.84
148 Pathogenesis of dengue: an alternative hypothesis. Southeast Asian J Trop Med Public Health 1990 0.83
149 Anticomplementary activity of dextran derivatives. Biomaterials 1985 0.83
150 Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm 2000 0.83
151 Molecular weight dependency of the acquired anticomplementary and anticoagulant activities of specifically substituted dextrans. Biomaterials 1987 0.83
152 Beneficial effect of human therapeutic intravenous immunoglobulins (IVIg) in mercuric-chloride-induced autoimmune disease of Brown-Norway rats. Clin Exp Immunol 1991 0.83
153 Human T lymphocytes expressing the C3b/C4b complement receptor type one (CR1, CD35) belong to Fc gamma receptor-positive CD4-positive T cells. Cell Immunol 1989 0.83
154 Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL. J Immunol 1992 0.83
155 Functional properties of soluble CD21. Immunopharmacology 1999 0.83
156 Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23. Eur J Immunol 1996 0.83
157 Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001 0.82
158 Lack of legal income is strongly associated with an increased risk of AIDS and death in HIV-infected injecting drug users. AIDS Care 1999 0.82
159 Lipid peroxidation in human immunodeficiency virus infection. J Acquir Immune Defic Syndr 1992 0.82
160 Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy. AIDS 1998 0.82
161 Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol 2003 0.82
162 Complement enhancement of HIV infection is mediated by complement receptors. Immunopharmacology 1993 0.82
163 Selective impairment of serum antibody repertoires toward muscle and thymus antigens in patients with seronegative and seropositive myasthenia gravis. Eur J Immunol 1998 0.82
164 Circulating immune complexes containing anti-VIII antibodies in multi-transfused patients with haemophilia A. Clin Exp Immunol 1980 0.82
165 The ability of Sephadex to activate human complement is suppressed in specifically substituted functional Sephadex derivatives. Mol Immunol 1988 0.82
166 Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b. Mol Immunol 1983 0.82
167 Secretory immunoglobulins in serum from human immunodeficiency virus (HIV)-infected patients. J Clin Immunol 1992 0.82
168 An ELISA method to measure total and specific human secretory IgA subclasses based on selective degradation by IgA1-protease. J Immunol Methods 2000 0.82
169 Platelet-activating factor enhances complement-dependent phagocytosis of diamide-treated erythrocytes by human monocytes through activation of protein kinase C and phosphorylation of complement receptor type one (CR1). J Biol Chem 1989 0.82
170 Restoration of normal interleukin-2 production by CD4+ T cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy. J Infect Dis 1999 0.82
171 Expression of CR1 (CD35) mRNA in podocytes from adult and fetal human kidneys. Kidney Int 1990 0.82
172 Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis. Eur J Immunol 1993 0.82
173 Expression of CR1 and CR2 complement receptors following Epstein-Barr virus infection of Burkitt's lymphoma cell lines. Scand J Immunol 1987 0.81
174 Platelet-dependent induction and amplification of polymorphonuclear leucocyte lysosomal enzyme release. Br J Haematol 1989 0.81
175 Increased frequency of the long (S) allotype of CR1 (the C3b/C4b receptor, CD35) in patients with systemic lupus erythematosus. Clin Exp Immunol 1992 0.81
176 Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 1985 0.81
177 Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor. Eur J Immunol 1984 0.81
178 Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS. J Infect Dis 1996 0.81
179 New anionic polyelectrolyte hydrogel for corneal surgery. J Biomed Mater Res 1997 0.81
180 Dissociation between complement activation, integrin expression and neutropenia during hemodialysis. Biomaterials 1999 0.80
181 Immunological and virological features of HIV-infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor-based therapy. HIV Med 2002 0.80
182 Decreased expression of the C3b/C4b complement receptor (CR1) in AIDS and AIDS-related syndromes correlates with clinical subpopulations of patients with HIV infection. AIDS 1987 0.80
183 The role of complement in immune clearance of blood cells. Springer Semin Immunopathol 1983 0.80
184 Pathophysiology of inhibitors to factor VIII in patients with haemophilia A. Haemophilia 2002 0.80
185 Altered self-reactive antibody repertoires are a general feature of patients with myelodysplastic syndrome. J Autoimmun 2001 0.80
186 Ontogenesis of the glomerular C3b receptor (CR1) in fetal human kidney. Clin Immunol Immunopathol 1985 0.80
187 Peripheral catabolism of CR1 (the C3b receptor, CD35) on erythrocytes from healthy individuals and patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1992 0.80
188 Neutralization of disease associated autoantibodies by an immunoglobulin M- and immunoglobulin A-enriched human intravenous immunoglobulin preparation. Scand J Immunol 2000 0.80
189 Variable sensitivity of lymphoblastoid cells to apoptosis induced by Viscum album Qu FrF, a therapeutic preparation of mistletoe lectin. Chemotherapy 2001 0.80
190 Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease. Clin Endocrinol (Oxf) 2001 0.79
191 Assessment of complement activation in clinical samples. Comparison of immunochemical and functional measurements of complement components with quantitation of activation fragments. J Immunol Methods 1992 0.79
192 Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur J Immunol 1998 0.79
193 Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases. J Autoimmun 1993 0.79
194 Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors. Am J Med 1991 0.79
195 The concept of anti-idiotypic regulation of selected autoimmune diseases by intravenous immunoglobulin. Clin Immunol Immunopathol 1989 0.79
196 Defective self-reactive antibody repertoire of serum IgM in patients with hyper-IgM syndrome. J Immunol 1999 0.79
197 Expression of CD21 is developmentally regulated during thymic maturation of human T lymphocytes. Int Immunol 1999 0.79
198 Decreased expression of C3b receptor (CR1) on erythrocytes of patients with systemic lupus erythematosus contrasts with its normal expression in other systemic diseases and does not correlate with the occurrence or severity of SLE nephritis. Complement 1986 0.79
199 Genital and oral erosions induced by foscarnet. Lancet 1990 0.79
200 Human diseases associated with C3 receptor deficiencies. Immunol Lett 1987 0.79
201 Effect of interferon and ribavirin on HIV viral load. AIDS 2000 0.79
202 Zidovudine inhibits functional extracellular monocytic interleukin-1. AIDS 1990 0.79
203 [Primary pulmonary hypertension in human immunodeficiency virus infection. Study of 9 cases amd review of the literature]. Rev Med Interne 2001 0.79
204 Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIg). Clin Immunol Immunopathol 1994 0.79
205 Membrane and soluble forms of CD21 (the C3dg/EBV receptor). Immunol Lett 1996 0.79
206 Normal human polyspecific immunoglobulin G (intravenous immunoglobulin) modulates endothelial cell function in vitro. Nephrol Dial Transplant 1995 0.79
207 Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA). Agents Actions 1991 0.79
208 A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines and idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg). J Autoimmun 1990 0.79
209 Soluble CD21 induces activation and differentiation of human monocytes through binding to membrane CD23. Eur J Immunol 1998 0.79
210 Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood 2000 0.78
211 Life-threatening intracranial bleeding associated with the presence of an antifactor VII autoantibody. Blood 1989 0.78
212 Biocompatibility of extracorporeal circuits in heart surgery. Transfus Sci 1990 0.78
213 Instability of natural antibody repertoires in systemic lupus erythematosus patients, revealed by multiparametric analysis of serum antibody reactivities. Scand J Immunol 1997 0.78
214 Sulfonated dextran inhibits complement activation and complement-dependent cytotoxicity in an in vitro model of hyperacute xenograft rejection. Mol Immunol 1996 0.78
215 Lack of evidence of a specific role for C4A gene deficiency in determining disease susceptibility among C4-deficient patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 2001 0.78
216 Altered antibody repertoires of plasma IgM and IgG toward nonself antigens in patients with warm autoimmune hemolytic anemia. Hum Immunol 2001 0.78
217 Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. J Neurol Neurosurg Psychiatry 1994 0.78
218 Genetic analysis of CR1 (the C3b complement receptor, CD35) expression on erythrocytes of HIV-infected individuals. AIDS 1989 0.78
219 Treatment of autoimmune diseases with normal immunoglobulin through manipulation of the idiotypic network. Clin Exp Immunol 1993 0.78
220 Complement activation and cytokine production as consequences of immunological bioincompatibility of extracorporeal circuits. Clin Mater 1993 0.78
221 Bacterial lipopolysaccharides alter human endothelial cell morphology in vitro independent of cytokine secretion. J Lab Clin Med 1991 0.77
222 Evidence for a restricted idiotypic and epitopic specificity of anti-thyroglobulin autoantibodies in patients with autoimmune thyroiditis. Eur J Immunol 1991 0.77
223 Complement C4A gene deletion in patients with systemic lupus erythematosus in France. J Rheumatol 1993 0.77
224 Decreased expression of the membrane inhibitor of complement-mediated cytolysis CD59 on T-lymphocytes of HIV-infected patients. AIDS 1992 0.77
225 Specific antibodies enhance alternative complement pathway activation by cuprophane. Nephrol Dial Transplant 1991 0.77
226 Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: effects on replacement therapy. Blood 1981 0.77
227 Histiocytosis-X cells express C3b, C3d, and C3bi receptor (CR1, CR2, and CR3) antigens. Arch Dermatol Res 1985 0.77
228 Ligation of CR1 (C3b receptor, CD35) on CD4+ T lymphocytes enhances viral replication in HIV-infected cells. Clin Exp Immunol 1996 0.77
229 Restricted genetic defects underlie human complement C6 deficiency. Clin Exp Immunol 2003 0.77
230 [Partial properdin deficiency revealed by a septicemia caused by Neisseria meningitidis]. Presse Med 1995 0.77
231 Analysis of antibody reactivities toward self antigens of IgM of patients with Waldenström's macroglobulinemia. Int Immunol 1997 0.77
232 Monoclonal anti-idiotypic antibodies against human anti-thyroglobulin autoantibodies recognize idiotopes shared by disease-associated and natural anti-thyroglobulin autoantibodies. Clin Immunol Immunopathol 1993 0.76
233 Activation-dependent antigenic changes of human C3. Complement Inflamm 1989 0.76
234 Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin G. Biochem Biophys Res Commun 1999 0.76
235 Idiopathic membranous glomerulonephritis is associated with altered patterns of self-reactive IgM and IgG antibody repertoires. Scand J Immunol 2001 0.76
236 The cytolytic C5b-9 complement complex: feedback inhibition of complement activation. Proc Natl Acad Sci U S A 1988 0.76
237 Complement activation and induction of interleukin-1 production during hemodialysis. Contrib Nephrol 1988 0.76
238 Induction of interleukin-1 during hemodialysis. Kidney Int Suppl 1993 0.76
239 The enhancing role of complement in human immunodeficiency virus infection: soluble recombinant CR1 (CD35) inhibits complement-mediated enhancement of infection of a CD4-positive T-cell line with human immunodeficiency virus-1. Scand J Immunol 2000 0.76
240 Broad alterations of self-reactive antibody-repertoires of plasma IgM and IgG in B-cell chronic lymphocytic leukemia (B-CLL) and B-CLL related target-restricted autoimmunity. Leuk Lymphoma 2001 0.76
241 Interactions between the alternative complement pathway and proteases of the coagulation system. Adv Exp Med Biol 1984 0.76
242 Mechanisms of immunomodulatory action of intravenous immunoglobulin in autoimmune and systemic inflammatory diseases. Ther Apher 1997 0.75
243 Dissociation between beta-2 microglobulin and IL-1 production in hemodialyzed patients. Nephrol Dial Transplant 1997 0.75
244 Modulation by complement of immune complex processing in health and disease in man. Prog Allergy 1986 0.75
245 Induction of IL-1 during hemodialysis: transmembrane passage of intact endotoxins (LPS). Kidney Int 1990 0.75
246 Modulation of the formation of the human amplification C3 convertase of complement by polycations. Immunology 1983 0.75
247 Intravenous immunoglobulin and immune response. Clin Exp Immunol 2014 0.75
248 Antiidiotypic suppression of autoantibodies with normal polyspecific immunoglobulins. Res Immunol 1989 0.75
249 Papanicolaou smears in human immunodeficiency virus-seropositive women during follow-up. Obstet Gynecol 1995 0.75
250 Modulation of the formation of the human C-3 amplification convertase of complement by polyelectrolytes. Agents Actions 1981 0.75
251 Enhancing role of complement in HIV infection. Clin Exp Immunol 1994 0.75
252 Idiotypic modulation of autoimmunity by therapeutic human immunoglobulin preparations (IVIg). Adv Nephrol Necker Hosp 1992 0.75
253 Membrane-bound hemagglutinin mediates antibody and complement-dependent lysis of influenza virus-treated human platelets in autologous serum. J Clin Invest 1984 0.75
254 Presence of the C3b complement receptor (CR1) antigen in the glomerular basement membrane of human fetal kidneys. Nephrol Dial Transplant 1988 0.75
255 Alterations in host defense mechanisms associated with cardiopulmonary bypass. Life Support Syst 1986 0.75
256 Can intravenous immunoglobulin treatment regulate autoimmune responses? Semin Hematol 1992 0.75
257 Catalytic activity of anti-thyroglobulin antibodies. Ann N Y Acad Sci 1995 0.75
258 [Immunomodulator effects of intravenous immunoglobulins in neurological autoimmune diseases]. Rev Neurol (Paris) 1995 0.75
259 Factor VIII inhibitor with catalytic activity towards factor VIII. Chem Immunol 2000 0.75
260 A synthetic dextran derivative inhibits complement activation and complement-mediated cytotoxicity in an in vitro model of hyperacute xenograft rejection. Transplant Proc 1996 0.75
261 Activation of the human classical complement pathway by a mouse monoclonal hybrid IgG1-2a monovalent anti-TNP antibody bound to TNP-conjugated cells. J Immunol 1985 0.75
262 [Regulation of autoreactivity by the idiotypic network and therapeutic modulation of autoimmunity by polyvalent intravenous immunoglobulins (IgIV)]. Rev Neurol (Paris) 1996 0.75
263 C3 receptor-mediated production and release of interleukin 1 by human monocytes. Prog Clin Biol Res 1989 0.75
264 Effect of substituted dextran derivative on complement activation in vivo. Biomaterials 1995 0.75
265 [Activation of the complement system during extracorporeal circulation in cardiac surgery]. Ann Chir 1986 0.75
266 Lack of behavioural risk factors for squamous intraepithelial lesions (SIL) in HIV-infected women. Int J STD AIDS 1997 0.75
267 Intravenous immune globulin in autoimmune uveitis. Ann Intern Med 1998 0.75
268 The use of intravenous immunoglobulins in the treatment of factor VIII inhibitors. Semin Hematol 1994 0.75
269 Efficacy and safety of desensitization to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. J Infect Dis 1995 0.75
270 Intravenous immunoglobulin (IVIg) in the treatment of autoimmune and inflammatory diseases. Clin Exp Rheumatol 1993 0.75
271 Polyreactivity of disease-associated anti-RBC IgG autoantibodies of patients with warm autoimmune haemolytic anaemia and natural anti-RBC IgG autoantibodies of healthy individuals. Scand J Immunol 2000 0.75
272 The mechanism of action of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy. Prog Clin Biol Res 1990 0.75
273 Hypocomplementaemia in a newborn caused by transplacental passage of maternal autoantibody with C3 nephritic factor (C3 NeF) activity. Nephrol Dial Transplant 1995 0.75
274 IVIg in the treatment of patients with factor VIII inhibitors. Adv Exp Med Biol 1995 0.75
275 Natural antibodies to factor VIII. Semin Thromb Hemost 2000 0.75
276 Low plasma levels of dehydroepiandrosterone (DHEA) and incidence of lipodystrophy. HIV Med 2001 0.75
277 Reconstitution of self-reactive antibody repertoires of autologous plasma IgM in patients with non-Hodgkin's lymphoma following myeloablative therapy. Clin Immunol 2001 0.75
278 Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz. HIV Med 2002 0.75
279 Neutralising antibodies against C3NeF in intravenous immunoglobulin. Lancet 1992 0.75
280 Complete inherited deficiency of the fourth complement component in a child with systemic lupus erythematosus and his disease-free brother in a north African family. J Clin Immunol 1994 0.75
281 Sporotrichosislike infection caused by Mycobacterium avium in the acquired immunodeficiency syndrome. Arch Dermatol 1993 0.75
282 [Reversible hyperaluminemia induced by ingestion of didanosine in a patient under chronic hemodialysis]. Presse Med 1994 0.75
283 Factor VIII inhibitor with catalytic activity towards factor VIII. Haematologica 2000 0.75
284 The concept of idiotypic vaccination against factor VIII inhibitors in haemophilia A. Haemophilia 2002 0.75
285 Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS 2000 0.75
286 The human glomerular C3 receptor. Mol Immunol 1984 0.75
287 Successful treatment of HIV-related thrombocytopenia with didanosine (ddI) J Acquir Immune Defic Syndr 1994 0.75
288 Specific antibodies enhance Sephadex-induced activation of the alternative complement pathway in human serum. Biomaterials 1988 0.75
289 [Immunomodulatory effects of intravenous immunoglobulins in autoimmune diseases]. Rev Med Interne 1999 0.75
290 Methylprednisolone inhibits granulocytopenia induced by infusion of complement-activated serum but not of complement-activated plasma in rabbits. Biomaterials 1989 0.75
291 [Toxic dermatitis caused by pyrimethamine in patients with acquired immunodeficiency virus infection]. Presse Med 1995 0.75
292 [Acalculous cholangitis and cholecystitis in two AIDS patients]. Presse Med 1991 0.75
293 [Structure and function of receptors for C3 cleavage fragments]. Nephrologie 1991 0.75
294 [Complement, a system of recognition of activation and amplification]. Ann Immunol (Paris) 1982 0.75
295 Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues. AIDS 2002 0.75
296 Methods for assessing monocytic cytokine production as an index of biocompatibility. Nephrol Dial Transplant 1994 0.75
297 Prevention of experimental autoimmune uveoretinitis by infusions of human therapeutic intravenous immunoglobulins in rats. Transplant Proc 1993 0.75
298 Is cancer an autoimmune process dependent on anti-apoptotic autoantibodies? Med Hypotheses 2000 0.75
299 [Induction of interleukin-1 synthesis. A new criterion of biocompatibility of extracorporeal circuits]. Presse Med 1991 0.75
300 Age-related changes in specificity of human natural autoantibodies to thyroglobulin. J Autoimmun 1993 0.75
301 Immunomodulation of autoimmune and systemic inflammatory diseases with intravenous immunoglobulin. Vox Sang 1994 0.75
302 Intravenous immunoglobulin (IVIg) modulates the expansion of V beta 3+ and V beta 17+ T cells induced by staphylococcal enterotoxin B superantigen in vitro. Scand J Immunol 1996 0.75
303 Analysis of self-reactive antibody repertoires in normal pregnancy. J Autoimmun 1998 0.75
304 High frequency of C4 "null" alleles in primary antiphospholipid syndrome. Ann Med Interne (Paris) 1996 0.75